Palvella Therapeutics Inc (PVLA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PVLA Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Palvella Therapeutics Inc manages cash inflows and outflows over time.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
6 Months
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-37.64
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation8.53
Income (Loss) from Equity Method Investments0.00
Increase (Decrease) in Derivative Liabilities0.23
Operating Lease Right of Use Asset Amortization-
Increase Decrease In Operating Lease Liabilities-
Operating Lease Right Of Use Asset Accretion-
Proceeds From Sale Of Fixed Assets Operating Activities-
Noncash Interest Expense Income Royalty Agreement2.04
Non Cash Interest Expense Convertible Notes-
Increase Decrease In Fair Value Of Convertible Notes Payable-
Change In Fair Value Of Derivative Liabilities- Contingent Value Right Liability-0.20
Costs To Issue Convertible Notes Charged To Expense-
Non Cash Lease Operating Expense0.04
Increase Decrease In Operating Lease Liability-0.05
Income taxes0.00
Losses/ -gains on Investments net-0.03
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable, Trade2.20
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.59
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.42
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.34
Payments for (Proceeds from) Other Operating Activities0.65
Discontinued operations0.00
Net Cash flow from Operating Activities-23.71
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds8.00
Payments to Acquire Marketable Securities-70.47
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-62.47
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-14.25
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock232.24
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.98
Proceeds From Issuance Of Common And Redeemable Convertible Preferred Stock-
Proceeds From Issuance Of Common And Preferred Stock-
Cash Acquired From Reverse Merger Transaction-
Payments Of Transaction Costs Associated With Pipe Financing-
Payment Of Transaction Costs To Issue Convertible Notes-
Proceeds From Amendment To Royalty Agreement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities216.01
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-23.71
Total Cash Flow129.82
4 historic quarters locked

Sign in to unlock the full Palvella Therapeutics Inc cash flow history.

About Palvella Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-331574

Figures are derived from filed reports and may be restated. Historical data is subject to revision.